James F. Oliviero III Sells 10,331 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 10,331 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $3.15, for a total value of $32,542.65. Following the sale, the chief executive officer now directly owns 3,775,019 shares in the company, valued at $11,891,309.85. This represents a 0.27 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Checkpoint Therapeutics Stock Performance

Shares of CKPT stock opened at $3.35 on Thursday. Checkpoint Therapeutics, Inc. has a fifty-two week low of $1.38 and a fifty-two week high of $4.50. The stock’s fifty day moving average price is $3.38 and its two-hundred day moving average price is $3.00. The company has a market cap of $163.58 million, a PE ratio of -1.82 and a beta of 1.36.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.08). On average, equities analysts predict that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Checkpoint Therapeutics

A number of hedge funds have recently made changes to their positions in CKPT. Geode Capital Management LLC lifted its stake in Checkpoint Therapeutics by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 445,111 shares of the company’s stock valued at $1,425,000 after purchasing an additional 17,460 shares during the last quarter. Virtu Financial LLC increased its holdings in shares of Checkpoint Therapeutics by 180.5% during the fourth quarter. Virtu Financial LLC now owns 38,157 shares of the company’s stock worth $122,000 after buying an additional 24,552 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Checkpoint Therapeutics in the 4th quarter valued at $67,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Checkpoint Therapeutics during the 4th quarter valued at $64,000. Finally, SBI Securities Co. Ltd. bought a new stake in Checkpoint Therapeutics during the 4th quarter worth $32,000. 22.00% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CKPT has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Monday, December 16th. D. Boral Capital assumed coverage on shares of Checkpoint Therapeutics in a research report on Monday, January 13th. They set a “buy” rating and a $9.00 price objective for the company. Finally, Lake Street Capital raised their target price on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a report on Monday, December 16th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.